Cargando…
Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors
SIMPLE SUMMARY: Ovarian cancer is the most lethal gynecologic cancer since it is often diagnosed at advanced stages. Current tools for diagnosis are currently insufficient and include physical examination, ultrasound and pelvic magnetic resonance imaging, as well as algorithms combining thoraco-abdo...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001105/ https://www.ncbi.nlm.nih.gov/pubmed/36900328 http://dx.doi.org/10.3390/cancers15051539 |
_version_ | 1784904052060979200 |
---|---|
author | Dabi, Yohann Favier, Amélia Razakamanantsoa, Léo Delbos, Léa Poilblanc, Mathieu Descamps, Philippe Golfier, Francois Touboul, Cyril Bendifallah, Sofiane Daraï, Emile |
author_facet | Dabi, Yohann Favier, Amélia Razakamanantsoa, Léo Delbos, Léa Poilblanc, Mathieu Descamps, Philippe Golfier, Francois Touboul, Cyril Bendifallah, Sofiane Daraï, Emile |
author_sort | Dabi, Yohann |
collection | PubMed |
description | SIMPLE SUMMARY: Ovarian cancer is the most lethal gynecologic cancer since it is often diagnosed at advanced stages. Current tools for diagnosis are currently insufficient and include physical examination, ultrasound and pelvic magnetic resonance imaging, as well as algorithms combining thoraco-abdomino-pelvic scans and blood markers. In this context, there is a need for new tools not only to assess the diagnosis but also to predict the response to chemotherapy and to detect recurrences. Previous studies have highlighted the potential value of non-coding RNAs (ncRNA) in tissue samples, but rarely in biofluids. In this review, we aim to summarize the existing literature on ncRNAs and ovarian tumors in biofluids. Most studies are focused on serum and blood with no data on other biofluids and with few ncRNAs investigated using qRT-PCR or microarray, which does not reflect the heterogeneity of ovarian cancers. ABSTRACT: Ovarian tumors are the most frequent adnexal mass, raising diagnostic and therapeutic issues linked to a large spectrum of tumors, with a continuum from benign to malignant. Thus far, none of the available diagnostic tools have proven efficient in deciding strategy, and no consensus exists on the best strategy between “single test”, “dual testing”, “sequential testing”, “multiple testing options” and “no testing”. In addition, there is a need for prognostic tools such as biological markers of recurrence and theragnostic tools to detect women not responding to chemotherapy in order to adapt therapies. Non-coding RNAs are classified as small or long based on their nucleotide count. Non-coding RNAs have multiple biological functions such as a role in tumorigenesis, gene regulation and genome protection. These ncRNAs emerge as new potential tools to differentiate benign from malignant tumors and to evaluate prognostic and theragnostic factors. In the specific setting of ovarian tumors, the goal of the present work is to offer an insight into the contribution of biofluid non-coding RNAs (ncRNA) expression. |
format | Online Article Text |
id | pubmed-10001105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100011052023-03-11 Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors Dabi, Yohann Favier, Amélia Razakamanantsoa, Léo Delbos, Léa Poilblanc, Mathieu Descamps, Philippe Golfier, Francois Touboul, Cyril Bendifallah, Sofiane Daraï, Emile Cancers (Basel) Review SIMPLE SUMMARY: Ovarian cancer is the most lethal gynecologic cancer since it is often diagnosed at advanced stages. Current tools for diagnosis are currently insufficient and include physical examination, ultrasound and pelvic magnetic resonance imaging, as well as algorithms combining thoraco-abdomino-pelvic scans and blood markers. In this context, there is a need for new tools not only to assess the diagnosis but also to predict the response to chemotherapy and to detect recurrences. Previous studies have highlighted the potential value of non-coding RNAs (ncRNA) in tissue samples, but rarely in biofluids. In this review, we aim to summarize the existing literature on ncRNAs and ovarian tumors in biofluids. Most studies are focused on serum and blood with no data on other biofluids and with few ncRNAs investigated using qRT-PCR or microarray, which does not reflect the heterogeneity of ovarian cancers. ABSTRACT: Ovarian tumors are the most frequent adnexal mass, raising diagnostic and therapeutic issues linked to a large spectrum of tumors, with a continuum from benign to malignant. Thus far, none of the available diagnostic tools have proven efficient in deciding strategy, and no consensus exists on the best strategy between “single test”, “dual testing”, “sequential testing”, “multiple testing options” and “no testing”. In addition, there is a need for prognostic tools such as biological markers of recurrence and theragnostic tools to detect women not responding to chemotherapy in order to adapt therapies. Non-coding RNAs are classified as small or long based on their nucleotide count. Non-coding RNAs have multiple biological functions such as a role in tumorigenesis, gene regulation and genome protection. These ncRNAs emerge as new potential tools to differentiate benign from malignant tumors and to evaluate prognostic and theragnostic factors. In the specific setting of ovarian tumors, the goal of the present work is to offer an insight into the contribution of biofluid non-coding RNAs (ncRNA) expression. MDPI 2023-02-28 /pmc/articles/PMC10001105/ /pubmed/36900328 http://dx.doi.org/10.3390/cancers15051539 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dabi, Yohann Favier, Amélia Razakamanantsoa, Léo Delbos, Léa Poilblanc, Mathieu Descamps, Philippe Golfier, Francois Touboul, Cyril Bendifallah, Sofiane Daraï, Emile Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors |
title | Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors |
title_full | Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors |
title_fullStr | Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors |
title_full_unstemmed | Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors |
title_short | Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors |
title_sort | insight on non-coding rnas from biofluids in ovarian tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001105/ https://www.ncbi.nlm.nih.gov/pubmed/36900328 http://dx.doi.org/10.3390/cancers15051539 |
work_keys_str_mv | AT dabiyohann insightonnoncodingrnasfrombiofluidsinovariantumors AT favieramelia insightonnoncodingrnasfrombiofluidsinovariantumors AT razakamanantsoaleo insightonnoncodingrnasfrombiofluidsinovariantumors AT delboslea insightonnoncodingrnasfrombiofluidsinovariantumors AT poilblancmathieu insightonnoncodingrnasfrombiofluidsinovariantumors AT descampsphilippe insightonnoncodingrnasfrombiofluidsinovariantumors AT golfierfrancois insightonnoncodingrnasfrombiofluidsinovariantumors AT touboulcyril insightonnoncodingrnasfrombiofluidsinovariantumors AT bendifallahsofiane insightonnoncodingrnasfrombiofluidsinovariantumors AT daraiemile insightonnoncodingrnasfrombiofluidsinovariantumors |